The findings, published in Nature Aging, illustrate the benefit of large datasets such as the EPND database to find important patterns in biological data.
Findings from Innovative Medicines Initiative project BigData@Heart underscore the importance of accounting for sex-based differences in medical research.
A new non-profit company is delivering fully characterised, lab-based paediatric tumour models for testing potential cancer therapies, thanks to the IMI ITCC-P4 project’s results.
Results from IMI project COMBACTE-CARE show that – if approved – a new combination of drugs could help in the fight against some of the most dangerous drug-resistant bacteria.
The standards were developed by a multi-stakeholder group including people living with asthma as well as doctors, pharmaceutical companies, and health policymakers.
The European Platform for Neurodegenerative Diseases has created a Cohort Catalogue to help to accelerate the hunt for biological markers of neurodegenerative diseases like Alzheimer's and Parkinson's diseases.
Using smartphones to self-report and monitor thinking difficulties could help to monitor and manage depression, according to new research from IMI project RADAR-CNS.
Data gathered during Innovative Medicines Initiative project DIRECT helped scientists to pinpoint genetic variants associated with a good response to diabetes drugs called GLP-1 agonists.
Innovative Medicines Initiative (IMI) project iConsensus draws on the agility and specialist knowledge of SMEs and the know-how of academic experts to make biological drug development faster, cheaper and more efficient.
The research, by Innovative Medicines Initiative (IMI) project IDEA-FAST, involved people with neurodegenerative and inflammatory diseases, where fatigue can have a major impact on patients’ quality of life.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.